Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
翰思艾泰生物醫藥科技(武漢)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3378)

(1) POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING HELD ON JUNE 24, 2026; AND (2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION

(1) POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING

The board of directors (the "**Board**") of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (the "**Company**") is pleased to announce the poll results of the annual general meeting (the "**AGM**") held at the Company's conference room at 3/F, Building A8, Phase II of Bio-Innovation Park, No. 1 Jiufeng 1st Road, East Lake New Technology Development Zone, Wuhan City, Hubei Province at 10:00 a.m. on Wednesday, June 24, 2026.

References are made to (i) the notice of the AGM, (ii) the circular (the "**Circular**") of the Company dated June 2, 2026. Unless otherwise defined, the terms used in this announcement shall have the same meanings as those defined in the Circular.

Attendance of the AGM

As at the time of convening the AGM, the total number of issued Shares was 136,218,830 Shares, among which 1,522,000 Shares were held as treasury Shares. The total number of Shares entitling the holders to attend and vote for or against the Resolutions at the Annual General Meeting was 134,696,830 Shares. The aforesaid 1,522,000 treasury Shares shall not be counted towards the number of Shares conferring on their holders the right to attend the AGM and vote on the Resolutions tabled thereat, and no voting rights shall be exercised in respect of such treasury Shares. To the best knowledge, information and belief of the Directors: (i) no Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the AGM; (ii) there was no Share entitling the holder thereto to attend the AGM and abstain from voting in favour of the resolutions proposed at the AGM under Rule 13.40 of the Listing Rules; and (iii) no Shareholders have indicated in the Circular that they intend to vote against or to abstain from voting on the resolutions proposed at the AGM.

Poll Results of the Resolutions Proposed at the AGM

The resolutions of the AGM were voted on by poll. The voting results of the resolutions proposed at the AGM are as follows:

ORDINARY RESOLUTIONS		Number of Votes (%)		
		For	Against	Abstain
1.	To consider and approve the report of the board of directors of the Company (the "**Board**") for the year 2025.	96,561,290 (100.0000%)	— (0.0000%)	— (0.0000%)
2.	To consider and approve the report of the supervisors committee of the Company for the year 2025.	96,561,290 (100.0000%)	— (0.0000%)	— (0.0000%)
3.	To consider and approve the annual report of the Company for the year 2025.	96,561,290 (100.0000%)	— (0.0000%)	— (0.0000%)
4.	To consider and approve the final financial report of the Company for the year 2025 and the financial budget report of the Company for the year 2026.	96,561,290 (100.0000%)	— (0.0000%)	— (0.0000%)
5.	To consider and approve the re-appointment of Ernst & Young as the auditor of the Company for the year 2026 and authorise the Board to determine its remuneration.	96,561,290 (100.0000%)	— (0.0000%)	— (0.0000%)
6.	To consider and approve the directors remuneration plan for the year 2026.	96,561,290 (100.0000%)	— (0.0000%)	— (0.0000%)
7.	To consider and approve 2025 Profit Distribution Plan.	96,561,290 (100.0000%)	— (0.0000%)	— (0.0000%)

SPECIAL RESOLUTIONS		Number of Votes (%)		
		For	Against	Abstain
8.	To consider and approve the amendments to the Articles of Association.	83,700,820 (86.6815%)	— (0.0000%)	12,860,470 (13.3185%)
9.	To consider and approve the granting of general mandate to issue additional H shares and sale or transfer of treasury shares.	83,700,820 (86.6815%)	— (0.0000%)	12,860,470 (13.3185%)
10.	To consider and approve the granting of general mandate to repurchase H shares.	83,700,820 (86.6815%)	— (0.0000%)	12,860,470 (13.3185%)

Notes:

(a) As more than one-half of the votes were cast in favour of the above resolutions No. 1 to No. 7 of the AGM, such resolutions were duly passed as ordinary resolutions of the Company.

(b) As more than two-thirds of the votes were cast in favour of the above resolutions No. 8 to No. 10 of the AGM, such resolutions were duly passed as special resolutions of the Company.

(c) As at the time of convening the AGM, the total number of issued Shares of the Company was 136,218,830 Shares and the number of treasury Shares held by the Company was 1,522,000.

(d) As at the time of convening the AGM, the total number of Shares (excluding treasury Shares) of the Company entitling the holders to attend and vote on the resolutions at the AGM was 134,696,830.

(e) The convening of the AGM and the procedure for holding of the AGM were in compliance with the requirements of PRC laws, administrative regulations and the Articles of Association.

(f) Tricor Investor Services Limited, the Company's H Share registrar, representatives of the Company's Shareholders and the Company's Supervisor acted as the counters and scrutineers for the vote-taking at the AGM.

(g) All Directors of the Board of the Company attended the AGM either in person or through video or teleconference.

(2) AMENDMENTS TO THE ARTICLES OF ASSOCIATION

A special resolution was duly passed by the Shareholders at the AGM to approve the proposed amendments to the Articles of Association as set out in the Circular. Accordingly, the amended Articles of Association shall become effective from the date of the AGM. The full text of the amended Articles of Association will be published on the websites of the Company (www.hanxbio.com) and the Stock Exchange (www.hkexnews.hk).

By order of the Board
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.
Dr. ZHANG Faming
Chairman and Executive Director

Hong Kong, June 24, 2026

As at the date of this announcement, the Board comprises (i) Dr. Zhang Faming, Dr. Henry Qixiang Li, Mr. Liu Min and Ms. Xiao Jieyu as executive Directors; (ii) Dr. Li Jian as a non-executive Director; and (iii) Dr. Bi Honggang, Mr. Chen Qifeng, Mr. Wong Sai Hung and Dr. Zhang Qiongguang as independent non-executive Directors.